Advertisement
Financing › Details
Antiverse–SEVERAL: investment, 202410 seed financing round 2nd extension £3.5m led by i&i Bio + Kadmos Capital
Period | 2024-10-15 | |
Predecessor | Antiverse–SEVERAL: investment, 202303 seed financing round extension $3m from existing + new investors | |
Money taker | Antiverse Ltd. | |
Money source | SEVERAL | |
Product | AI-based drug discovery / AI-based drug development | |
Product 2 | venture capital | |
Person | Zahrádka, Jaromír (i&i 202303 CEO + Partner) | |
Antiverse Ltd.. (10/15/24). "Press Release: Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform". Cardiff.
This Brings The Company's Total Financing To £7.2M ($10.1M). The Funding Will Progress Antibodies Targeting Several G-Protein Coupled Receptors and Ion Channels To The Clinic With Pharma Collaboration
Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many in partnership with pharmaceutical companies. The latest investment round was led by i&i Biotech Fund I (i&i Bio) and Kadmos Capital, with additional investment from existing investors InnoSpark Ventures, UKI2S (managed by Future Planet Capital), Tensor Ventures, and AngelHub. This brings the total equity financing raised to £7.2M ($10.1M).
The funding will be used to expand the Company’s laboratory and machine learning teams, bolstering the development of its internal assets against G-protein-coupled receptors (GPCRs) and ion channels towards the clinic, as well as facilitating ongoing collaborations with pharma and biotech companies. In addition, the Company aims to improve the predictive accuracy of its design platform, focusing on curating training data. Lastly, Antiverse has opened new facilities in Boston, MA, and Prague, Czech Republic, demonstrating its expansion.
Murat Tunaboylu, Co-Founder and CEO of Antiverse said: “A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe.”
Antiverse uses a machine-learning-centred approach to design antibodies for challenging targets, helping to bring needed therapies to patients. The current version of the platform uses ‘target-specific libraries’. These libraries are designed by using structural and sequence data to generate a library with high confidence against the target. This enhances the predictive accuracy compared to traditional antibody libraries, enabling Antiverse to design antibodies for many challenging targets, including GPCRs and ion channels. The platform accelerates the antibody discovery process to 6 months.
Jaromir Zahradka, CEO at i&i Bio, commented: “Antiverse has made significant progress in the field of antibody design. Antiverse's mission to make GPCRs druggable focuses on a key issue and we are pleased to be supporting them.”
John Gebeily, Operating Partner at Kadmos Capital, added: “Antiverse's AI-driven antibody design platform demonstrates significant potential in advancing the development of novel antibody therapeutics, particularly for complex drug targets. We're excited to support Murat and the team in their effort to significantly accelerate the development of life-saving treatments, and have a transformative impact on the pharmaceutical industry.”
[photo]
Left: Murat Tunaboylu, Chief Executive Officer at Antiverse. Middle: John Gebeily, Operating Partner at Kadmos Capital. Right: Jaromir Zahradka, CEO at i&i Bio.
Media Contact:
Name: Luke Bateman
Title: Marketing Coordinator
Email: [email protected]
About Antiverse www.antiverse.io
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against challenging targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
X | LinkedIn
About Kadmos Capital www.kadmoscapital.com
Kadmos Capital is an FCA regulated venture capital firm based in London. It focuses on early-stage deep-tech companies with hyper growth potential and positive impact. The fund aims to capitalize on Europe’s accelerating growth in Venture Capital investments.
About i&i Biotech Fund I (i&i Bio) www.inibio.eu.
i&i Bio is a Luxembourg-based venture capital firm that invests in innovative European life sciences companies focused on drug discovery, medical devices, diagnostics, and digital health. The Fund was created thanks to the cooperation of the biotech incubator i&i Prague and the European Investment Fund. With over € 53 million under management, i&i Bio plans to invest in about 20 early-stage companies. i&i Bio is led by an experienced team of professionals with backgrounds in private equity, healthcare and venture capital supporting entrepreneurs on their journey to global success. Thanks to close cooperation with the fund’s main sponsor, the biotech academic incubator i&i Prague, i&i Bio is supporting and advancing transformative Central European technology companies.
About European Investment Fund
i&i Bio is supported by an investment from the EIF, with the support of:
> lnnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing; and
> the Pan-European Guarantee Fund (EGF), implemented by the EIF with the financial support of the Participating Member States. The objective of EGF is to respond to the economic impact of the COVID-19 pandemic by ensuring that companies in the Participating Member States have sufficient short-term liquidity available to weather the crisis and are able to continue their growth and development in the medium to long-term.
More information can be found here.
Record changed: 2024-11-06 |
Advertisement
More documents for Antiverse Ltd.
- [1] Antiverse Ltd.. (10/15/24). "Press Release: Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform". Cardiff....
- [2] Antiverse Ltd.. (10/16/23). "Press Release: Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics". Cardiff & Cambridge, MA....
- [3] Antiverse Ltd.. (3/1/23). "Press Release: Antiverse Raises Funding and Demonstrates Therapeutic Antibody Identification with AI-driven Drug Discovery platform". Cardiff....
- [4] Antiverse Ltd.. (3/15/21). "Press Release: Antiverse Raises £1.4 Million ($2 Million USD) to Advance Its AI Antibody Drug Discovery Platform"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top